FDA Approves New Indication for Promacta (eltrombopag) for Severe Aplastic Anaemia

London, UK -- 26 August 2014 -- GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for the once-daily use of Promacta in patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy .1 SAA is a blood disorder where the bone marrow ... (more)

http://ift.tt/1nAqJMU